^
Association details:
| Biomarker: | KRAS G12A |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Excerpt:
Each mutation was associated with worse DFS compared with KRAS/BRAF-wild type (all HR point estimates >1). Five of the six KRAS codon 12 mutations (c.34G>A [p.G12D], c.35G>T [p.G12V], c.34G>T [p.G12C], c.35G>C [p.G12A], c.34G>C [p.G12R]) demonstrated a statistically significant association with worse DFS in univariate and multivariate analysis.
DOI:
10.1158/1078-0432.CCR-13-3140
Source:
Title:
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer
Excerpt:
Baseline mutations in genes: BRAF, KRAS, NRAS. Mutations detected in tumor tissue during routine work‐up and in cfDNA prior to start of cetuximab monotherapy...Our analysis of patients’ baseline ctDNA revealed three additional patients who had KRAS mutations (KRAS p.G12A, p.G61H, and a combination of the two) that had not been detected in tumor tissue...While almost all patients with additional KRAS or BRAF mutations were resistant to therapy, we also had one patient with clinical benefit who nevertheless had a polyclonal KRAS mutation (p.G61H and p.G12A) in ctDNA...
DOI:
10.1002/1878-0261.12550
Trial ID: